Manage Account
Change Password
Sign Out
Hypersecretory conditions
Adult: Initially, 1 mg/kg/hr via infusion, may increase rate at increments of 0.5 mg/kg/hr after 4 hours, as necessary. Doses up to 2.5 mg/kg/hr and infusion rates up to 220 mg/hr may be given.
Intravenous
Prophylaxis of gastrointestinal haemorrhage from stress ulceration
Adult: 50 mg via slow IV inj as priming dose, followed by 0.125-0.25 mg/kg/hr via continuous infusion. Substitute oral therapy as soon as possible.
Oral
NSAID-associated ulceration
Adult: 150 mg bid or 300 mg at bedtime for 8 weeks.
Oral
Dyspepsia
Adult: 150 mg bid for up to 6 weeks. For short-term symptomatic relief: 75 mg repeated up to Max 4 doses daily, as necessary. Treatment duration: Up to 2 weeks of continuous use at one time.
Oral
Gastro-oesophageal reflux disease
Adult: 150 mg bid or 300 mg at bedtime for up to 8 weeks or if necessary, up to 12 weeks. Alternatively, 75 mg daily, as needed, no additional dose within 24 hours. For erosive esophagitis: May increase usual dose to 150 mg 4 times daily for up to 12 weeks; maintenance: 150 mg bid.
Child: As tab or oral solution: 3-11 years 5-10 mg/kg daily as in 2 divided doses up to Max of 600 mg daily; ≥12 years Same as adult dose.
Child: As tab or oral solution: 3-11 years 5-10 mg/kg daily as in 2 divided doses up to Max of 600 mg daily; ≥12 years Same as adult dose.
Oral
Duodenal ulcers associated with H. pylori infection
Adult: 300 mg at bedtime or 150 mg bid given with oral amoxicillin and metronidazole for 2 weeks. Continue therapy without antibiotics for another 2 weeks. For patient with history of recurrent ulcer and have responded to short-term therapy, reduce dose to 150 mg at bedtime.
Oral
Prophylaxis of gastrointestinal haemorrhage from stress ulceration
Adult: 150 mg bid as a substitute for IV inj once oral therapy is possible.
Oral
Prophylaxis of acid aspiration during general anaesthesia
Adult: 150 mg given 2 hours prior to induction of anaesthesia and, and preferably, a 150 mg dose on the previous evening. In obstetric patients, 150 mg may be given at the start of labour and may be repeated at 6-hour intervals, as necessary.
Oral
Benign gastric and duodenal ulceration
Adult: Initially, 150 mg bid or 300 mg at bedtime for at least 4 weeks. May increase dose up to 300 mg bid, as necessary. Maintenance: 150 mg daily at bedtime.
Child: As tab or oral solution: 3-11 years 4-8 mg/kg daily in 2 divided doses to a Max of 300 mg daily for 4 weeks or up to 8 weeks if needed; ≥12 years Same as adult dose.
Child: As tab or oral solution: 3-11 years 4-8 mg/kg daily in 2 divided doses to a Max of 300 mg daily for 4 weeks or up to 8 weeks if needed; ≥12 years Same as adult dose.
Oral
Hypersecretory conditions
Adult: Initially, 150 mg bid or tid, may be increased if necessary, up to 6,000 mg daily.
Parenteral
Benign gastric and duodenal ulceration
Adult: Up to 50 mg via IM or IV inj over 2 minutes or 25 mg/hour via intermittent IV infusion. Dose may be repeated 6-8 hourly.
Child: 6 months-11 years Initially, 2 or 2.5 mg/kg (Max 50 mg) via slow IV inj over 2 minutes. Maintenance of pH>4: 1.5 mg/kg via intermittent infusion 6-8 hourly. Alternatively, 0.45 mg/kg as loading dose via slow IV inj over 2 minutes followed by 0.15 mg/kg/hr via continuous infusion. ≥12 years Same as adult dose.
Child: 6 months-11 years Initially, 2 or 2.5 mg/kg (Max 50 mg) via slow IV inj over 2 minutes. Maintenance of pH>4: 1.5 mg/kg via intermittent infusion 6-8 hourly. Alternatively, 0.45 mg/kg as loading dose via slow IV inj over 2 minutes followed by 0.15 mg/kg/hr via continuous infusion. ≥12 years Same as adult dose.
Parenteral
Prophylaxis of acid aspiration during general anaesthesia
Adult: 50 mg via IM or slow IV inj 45-60 minutes prior to induction of anaesthesia.
